Towards less mutilating treatments in patients with advanced non-melanoma skin cancers by earlier use of immune checkpoint inhibitors.

Autor: Hooiveld-Noeken JS; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Eggen AC; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Rácz E; Department of Dermatology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., de Vries EGE; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Reyners AKL; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Jalving M; Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. Electronic address: m.jalving@umcg.nl.
Jazyk: angličtina
Zdroj: Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2022 Dec; Vol. 180, pp. 103855. Date of Electronic Publication: 2022 Oct 17.
DOI: 10.1016/j.critrevonc.2022.103855
Abstrakt: Merkel cell carcinoma (MCC), advanced cutaneous squamous cell carcinoma (cSCC), and advanced basal cell carcinoma (BCC) are rare, and the often frail patients may require potentially mutilating local treatments. Immune checkpoint inhibitors (ICIs) are effective in melanoma and are moving towards the neoadjuvant setting. This systematic review explores data supporting the transition of ICIs from the metastatic to the (neo)adjuvant setting non-melanoma skin cancer (NMSC) and describes how knowledge from melanoma can be utilized. ICI response rates in advanced NMSC and melanoma are comparable. Five early phase studies show effectivity of neoadjuvant ICIs in melanoma and adjuvant treatment is standard-of-care. Eight adjuvant and 12 neoadjuvant ICI studies are ongoing for NMSC. Encouragingly, data from two small neoadjuvant ICI studies in NMSC, demonstrated complete responses in approximately half of patients. In conclusion, neoadjuvant ICI treatment has potential to avert mutilating treatments in NMSC. Progress can be accelerated by learning from melanoma.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Elisabeth de Vries reports financial support was provided by the Dutch Cancer Society. Elisabeth de Vries reports a relationship with Daiichi Sankyo, NSABP, and Sanofi that includes: consulting or advisory (all paid to the institution). Mathilde Jalving reports a relationship with GSK, AstraZenica, BMS, Pierre Fabre that includes: consulting or advisory (all paid to the institution). Elisabeth de Vries reports a relationship with Amgen, AstraZeneca, Bayer, Chugai Pharma, Crescendo, CytomX Therapeutics, G1 Therapeutics, Genentech, Nordic Nanovector, Radius Health, Regeneron, Roche, Servier, and Synthon that includes: funding grants (all paid to the institution).
(Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: